 Half the participants will receive CyColTM and half will receive placebo. At the end of treatment 4 weeks study participants will be reassessed again and the findings in those who received CyColTM will be compared with those who received placebo. Any side effects experienced during the study and the safety of treatment with CyColTM will also be evaluated. 